The stress of working long hours is more likely to lead to a stroke than a heart attack, UK researchers report.
The first real-world study of its kind revealed that rivaroxaban, marketed as Xarelto, can reduce the risk of stroke and major bleeding in patients with atrial fibrillation (AF) – a group that is five times more likely to suffer a stroke compared to the general population.
Research has established that various parts of the trigeminal system are responsible for peripheral symptoms of migraine. Treatment with corticosteroids reduces the symptoms of migraine, but the treatment is associated with long-term side effects.
Barry Greenberg, MD, UCSD Sulpizio Cardiovascular Center, La Jolla, California, USA, presented about the Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Phase 2b (CUPID 2) gene transfer study at the European Society of Cardiology Congress (ESC) 2015.
With the exception of perhaps stroke neurologists, who see the devastating effects of stroke every day, many other physicians let fear guide their anticoagulation treatment decisions, according to the experts.
In atrial fibrillation, aspirin could double a patient’s risk for bleeding. And yet, it is still used all the time. Hear the experts discuss the importance of using a “real” anticoagulant for patients who need to be anticoagulated.
Researchers who assessed patients undergoing percutaneous coronary intervention (PCI) reported that extending the use of a particular anti-clotting medication following the procedure did not lead to additional benefits.
The Sanofi/Regeneron PCSK9 inhibitor alirocumab (Praluent)— approved in July in the US — lowered cholesterol in patients with familial hypercholesterolemia to levels “unreachable with statins” researchers said at the European Society of Cardiology meeting in London, UK.
The EXAMINATION trial showed a second generation drug-eluting stent did better than a bare-metal stent, researachers reported at ESC 2015 in London, UK.